Time to secondary progression in patients with MS who were treated with first generation immunomodulating drugs

This study from Sweden looked at the time interval from onset to secondary progression (SP) in a cohort of contemporary relapsing-remitting MS patients treated with disease modifying therapy and a historical population-based incidence cohort.

They analysed the difference in time to secondary progressive MS, termed the “period effect”, within a 12 year survival analysis. They found that there was a convincing “period effect”, with a longer time to the onset of SP in the contemporarily-treated than in the historical patient data. The “period effect” was seen across the entire severity spectrum.

They found no convincing evidence for a large imbalance between groups of benign cases and suggest that the observed delay to SP was likely due to the sustained use of disease modifying therapy.

Authors: Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, Fagius J, Fredrikson S, Landtblom AM, Malmeström C, Martin C, Piehl F, Runmarker B, Stawiarz L, Vrethem M, Nerman O, Andersen O.

Mult Scler. 2012 Nov 1. [Epub ahead of print]

Read the abstract


Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial